Kornimate/medical-research-clean huggingface dataset:
pilot study using a pulse oximeter derived photo-plethysmographic waveform to guide hemodialysis ultrafiltration

Conditions: Intradialytic Hypotension; Hypervolemia

Summary: the purpose of this study is to use the photo-plethysmographic \[ppg\] waveform signal to guide the dialysis and ultrafiltration \[uf\] of chronic maintenance hemodialysis patients, and to further the investigators understanding of homeostasis in hemodialysis. the investigators hypothesize that the signals generated from the ppg device along with traditional monitoring and nursing judgment, will allow experienced, oriented staff to anticipate hemodynamic instability, intervene to prevent or mitigate the intradialytic hypotention \[idh\], forestalling the onset of non-facilitating compensatory reflexes that preclude the patient from achieving an appropriate post-dialysis weight consistent with euvolemia. furthermore, it is hypothesized that the nephrologist and staff will be able to wean patients from anti-hypertensive medications and craft patient specific dialysis orders and uf profiles that achieve consistent, comfortable treatment to appropriate end points. the study aims include: aim 1: to confirm the temporal sequence of ppg signals and changes in bp in routine hemodialysis. aim 2: to refine further the predictive algorithms of ppg, augmented with continuous cardiac event monitoring (pre-intra-post hemodialysis) aim 3: to develop targeted interventions to reverse the cardiovascular stress indicated by the ppg and to maintain perfusion. aim 4: to develop care paths approved by the medical staff and primary care nephrologist allowing rns to respond to signals from the ppg.


Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. on dialysis \> 6 months with a stable dialysis program 3. consistent achievement of a spkt/v ≥ 1.2 4. hgb ≥ 10 gm% ± esa support 5. consistent failure to achieve a post weight ≤ dry weight + 0.5kg 6. able to give informed consent directly 7. frequent hypotensive reactions (≥ 1 / treatment in 4 of last 8 treatments) * symptoms of hypotension * intervention administered because of idh (saline, "turn downs, early termination, trendelenberg position) * drop in bp irrespective of symptoms. sbp \ 110 mmhg; sbp \< 85 mmhg or 15 mmhg drop from start if starting bp ≤ 110 mmhg. * or judged by the nursing staff to be difficult to achieve dry weight. exclusion criteria: 1. dialysis catheter access that may interfere with continuous data collection, per pi determination. (catheter access is a relative exclusion based on the history of catheter performance.) 2. cognitive impairment precluding cooperation, and consent 3. restless or unlikely to wear the monitor head-band 4. too unstable in the judgment of their nephrologist to be included in a study of this nature.
innova breeze®-based roadmap for peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: over the past decade, interventional endovascular treatment, whenever feasible, has become the first line management in the treatment of lower extremity arterial disease (lead) for many indications. growth of endovascular therapy was based on shorter hospital length of stay and lower complications rates. this minimally invasive procedure allows the revascularization of the lower limbs under fluoroscopy guidance, with injection of iodinated contrast allowing to analyze the arteries. however, many of these patients present renal insufficiency which could be worsened due to the iodinated contrast injections during the endovascular procedure for lead. consequently, the vascular interventionalist should find a way to achieve patient revascularization while minimizing iodinated contrast injections in order to maintain the renal function. the aim of this study is to compare the amount of iodine contrast used during lead endovascular revascularization with and without the innova breeze® and blended roadmap software.


Eligibility criteria:
inclusion criteria: * patient ≥ 18 years * patient has a history of symptomatic peripheral arterial disease (rutherford classification 2-6) * patients with indication of femoropopliteal revascularization according the european guidelines (1) * patient agrees to undergo all protocol required follow-up examinations and requirements at the investigational site * french-speaking patient * patient is affiliated to the social security or equivalent system * patients is able and willing to give free, informed and express oral consent * iliac and/or below the knee lesions are allowed in combination to femoropopliteal lesions exclusion criteria: * upper limb approach * femoral antegrade approach * pregnant or breastfeeding woman * adult under guardianship or trusteeship * iodinated contrast allergy * reduction in estimated glomerular filtration ratio (egfr) ≤ 29 ml/min/m2 (11) * patients included in other studies which interact with intraoperative imaging protocols * concurrent participation in an interventional (drug or device) study for which the follow-up period is not complete. * patient under tutorship or curatorship * patient deprived of liberty
phosphorus absorption in healthy adults and in patients with moderate chronic kidney disease

Conditions: Chronic Kidney Disease Mineral and Bone Disorder

Summary: chronic kidney disease (ckd) affects approximately 26 million americans with many more at risk for disease development. elevated serum phosphorus (p) and related abnormalities in p homeostasis due to progressive loss of kidney function are primary driving forces behind cardiovascular dysfunction and mortality in ckd patients. intestinal p absorption is an critical aspect in p homeostasis but has been understudied, particularly in the early stages of ckd progression. this study aims to determine p absorption in patients with moderate ckd compared to healthy adults.


Eligibility criteria:
inclusion: men and women ages 30-75 years old, any race moderate ckd, based on the last set of labs done in the past year, defined as: glomerular filtration rate (gfr) category g3a (egfr 45-59 ml/min) with a2 or a3 albuminuria or proteinuria by positive dipstick or urine protein/creatinine ratio (upcr); -or- g3b (egfr 30-44 ml/min), with or without evidence of albuminuria (any a1-a3) or proteinuria. (figure 1) -or- healthy control with no diagnosis or evidence of ckd female subjects must be post-menopausal, surgically sterile, or confirmed not pregnant by pregnancy test and not breastfeeding. subjects must be on stable doses of medications (except those noted in exclusion criteria) for at least 6 weeks prior to the study exclusion: plans to initiate dialysis within 6 months labs based on the last set done in the past year: hypercalcemia defined as serum calcium \> 10.5 mg/dl hyperkalemic \> 5.5 mg/dl prescribed a phosphate binder medication small bowel resection, bariatric surgery. medically unstable or poorly controlled hypertension, diabetes, or gastrointestinal disorders in the opinion of the physicians on the study team calcitriol, ergocalciferol, cholecalciferol, vitamin d analogs, calcimimetics, pth analogues, calcium supplements, multivitamins/mineral and other medications that may alter phosphorus metabolism - must be off for at least 6 weeks prior to study

Keywords: chronic kidney disease ckd renal failure phosphorus phosphate intestinal absorption
sutureless intrascleral intraocular lens fixation and modified iris cerclage pupilloplasty

Conditions: Aphakia; Mydriasis

Summary: in this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, best corrected visual acuity, intraocular pressure, pupil diameter, corneal endothelial cell count, fundus examination, and photophobia score, were collected. those who met the recruitment criteria underwent modified iris cerclage pupilloplasty. the modified iris cerclage pupilloplasty was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.


Eligibility criteria:
inclusion criteria: * diagnosis of aphakia * permanently dilated pupils * history of phacoemulsification and pars plana vitrectomy surgeries for lens dislocation after blunt trauma exclusion criteria: * iris defects * severe diseases such as cyclodialysis cleft, uncontrolled iop, retinal detachment * poorly controlled systemic diseases such as diabetes and hypertension * corneal endothelial cell counts of \<1000/mm2 * \<6 months of follow-up

Keywords: aphakia mydriasis
writing about experiences with ovarian cancer

Conditions: Ovarian Cancer

Summary: this online study aims to understand whether writing about one's experiences with ovarian cancer may be beneficial for psychological and physical wellbeing in women with a history of ovarian cancer. investigators are also interested in studying how certain individual characteristics may impact the effectiveness of writing. participants will be asked to complete an initial survey (15 min), followed by writing about their experiences with ovarian cancer on four occasions (20 - 25 min each), over the course of two weeks. a final survey (10 min) will be completed one month afterwards.

the purpose of this randomized controlled experiment is to examine the effects of writing about experiences with ovarian cancer on psychological and physical outcomes in english-speaking women with a history of ovarian cancer. it will also examine how certain individual characteristics may impact the effectiveness of the writing interventions for different women. after completing an initial survey, women will be asked to write about their experiences with ovarian cancer on 4 separate occasions of 20-25 min each in the course of 2 weeks. a final survey will be completed one month after the last writing session. the entire study will be conducted online.

Eligibility criteria:
inclusion criteria: * women with a history of ovarian cancer (any stage) * at least 18 years old * english-speaking/can comfortably read and write in english * able to provide informed consent * internet access * valid email address * any region/country exclusion criteria: * minors (younger than 18) * lack of english proficiency * inability to provide informed consent * male

Keywords: ovarian cancer expressive writing writing interventions psychosocial support
development of an epileptic seizure detection algorithm by continuous analysis of the electrocardiogram

Conditions: Seizures; Epilepsy; Electrocardiography

Summary: the aim of our project is to develop an epileptic seizure detection algorithm based on the the continuous analysis of the electrocardiogram

in a first step, the team will build a multi-parametric algorithm on existing records issued from the epilepsy monitoring units. each selected record will be analyzed by emu medical team in order to detect seizure on the eeg. the algorithm will adapt in order to obtain the best sensitivity and specificity regarding seizure detection. in a second step,algorithm will validate on a cohort of other recordings in patients with epilepsy

Eligibility criteria:
inclusion criteria: * patients with epilepsy * with a long-term video-eeg recording * 1 (or more) seizure (s) recorded * onset seizure clearly defined on the basis of the eeg exclusion criteria: * bad quality of the electrocardiogram recording * pace-maker * non sinus rhythm

Keywords: seizure detection
the polarization and expression of chemokine receptors of t help cell in the pathogenesis of acute and chronic gvhd

Conditions: Hematopoietic Stem Cell Transplantation, Graft-Versus-Host Disease

Summary: the purpose of this study is to see the correlation of polarization and the expresison of chemokine receptors of t help cells after allogeneic hematopoietic stem cell transplantation and clinical course graft-versus-host disease.


Eligibility criteria:
inclusion criteria: * patient received allogeneic stem cell transplantation at cmuh * can be regularly followed at cmuh exclusion criteria: * patient who do not want to enter in this study

Keywords: cytokine t-cell chemokine graft-versus-host disease
a survey to evaluate diabetes management, control, chronic complications, psychosocial aspects of diabetic subjects in india

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is conducted in asia. the aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in india. perceptions and practices of physicians and subjects about diabetes management will also be evaluated.


Eligibility criteria:
inclusion criteria: * patients should have visited the centre at least once in the last 3-6 months apart from the initial visit * first twenty patients of diabetes visiting the centre during the data collection period * patients willing to sign the informed consent form exclusion criteria: * repetition of any patient as patients should not be included twice for any reason * unwilling to participate or unable to comply with protocol requirements
a study of incb050465 in japanese subjects with previously treated b-cell lymphoma (citadel-111)

Conditions: Lymphoma

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of parsaclisib in the treatment of japanese participants diagnosed with previously-treated b-cell lymphoma.


Eligibility criteria:
inclusion criteria: * first generation japanese; subject was born in japan and has not lived outside of japan for \> 10 years, and subject can trace maternal and paternal japanese ancestry. * histologically confirmed aggressive/indolent dlbcl, fl, mzl, or mcl. * previously received at least 1 prior line of systemic therapy with documented progression, and there is no further effective standard anticancer therapy available. * willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue. * life expectancy \> 3 months. * eastern cooperative oncology group performance status of 0 to 2. * adequate hematologic, hepatic, and renal function. exclusion criteria: * evidence of transformed non-hodgkin's lymphoma histologies. * histologically confirmed, rare non-hodgkin's b-cell subtypes. * history of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease. * prior treatment with idelalisib, other selective pi3kδ inhibitors, or a pan-phosphatidylinositol 3 kinase (pi3k) inhibitor. * allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug. * active graft-versus-host disease. * history of stroke or intracranial hemorrhage within 6 months of study drug administration. * chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment or exposure to a live vaccine within 30 days of the date of the first dose of study drug. * known human immunodeficiency virus infection. * evidence of hepatitis b virus or hepatitis c virus infection or risk of reactivation.

Keywords: diffuse large b-cell lymphoma (dlbcl) follicular lymphoma (fl) marginal zone lymphoma (mzl) mantle cell lymphoma (mcl) phosphatidylinositol 3-kinase (pi3k)
aedv registry of primary cutaneous lymphoma

Conditions: Lymphoma, T-Cell, Cutaneous; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Sezary Syndrome; Lymphoma, Extranodal NK-T-Cell; Lymphoma, B-Cell

Summary: registry of patients with primary cutaneous lymphoma seen at participating centers in spain. the registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies.

registry of patients with primary cutaneous lymphoma seen at participating centers in spain. the registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies. data is entered in the registry in each of the participating cutaneous lymphoma clinics. these data are updated at least yearly. participants receive specific training before starting, and there is an online continuous monitoring system.

Eligibility criteria:
inclusion criteria: * all consecutive patients with primary cutaneous lymphoma exclusion criteria: * not willing to participate
efficacy and safety of spd465 in adults with moderately symptomatic adhd.

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to assess the safety and effectiveness of spd465 compared to placebo (a capsule with no medication in it) in the treatment of adhd. the study will also look at how spd465 affects the participants sleep and how they perceive their quality of life.


Eligibility criteria:
inclusion criteria: * primary diagnosis of adhd * baseline adhd-rs-iv score \>= 32 * non-pregnant females of childbearing potential must comply with contraceptive restrictions. exclusion criteria: * significantly underweight or morbidly obese * comorbid psychiatric diagnosis with significant symptoms such as axis ii disorders or severe axis i disorders * history of seizure, tic disorder, or a current diagnosis and/or family history of tourette's disorder * females who are pregnant or lactating
t-cell subsets in rheumatoid arthritis patients on long-term anti-tnf or il6-receptor-blocker therapy

Conditions: Rheumatoid Arthritis

Summary: data on the impact of biological therapies, especially of il6-blocker treatment, on the t-cell phenotype in rheumatoid arthritis (ra) are limited, inconclusive, and mainly involve short-term follow-up. here, the investigator prospectively measure the percentages of 15 circulating t-cell subtypes using flow cytometry. the investigators aim to obtained transversal and longitudinal data in 30 anti-tnf responders, 19 secondary anti-tnf-non-responders, 43 il6r-antagonist-responders before, 8 weeks and, after, at least, 6 months of biological therapy. these are then compared with results obtained in early, untreated ra patients and gender-and-age matched healthy controls.


Eligibility criteria:
inclusion criteria for patients: * diagnosis of rheumatoid arthritis classified according to the 2010 acr/eular classification criteria for ra * biological treatment with anti-tnf therapy (adalimumab or certolizumab pegol or etanercept or infliximab or golimumab) or anti-il-6r agent (tocilizumab) inclusion criteria for healthy controls: * negative history of ra symptoms * negative status upon detailed physical and laboratory examination including normal crp and esr values exclusion criteria: * other autoimmune comorbidity * lack of informed consent
management of plasma cell gingivitis by two surgical techniques

Conditions: Plasma Cell Gingivitis

Summary: two surgical protocols for management of plasma cell ginigivitis; either by surgical enblock resection of cold laser resection

tow groups will be included the first will have six cases and second will have six cases. the first will be treated by ordinary surgical resection and second will be removed using soft tissue laser.

Eligibility criteria:
inclusion criteria: - patients suffering from the plasma cell gingivitis exclusion criteria: - patient not eligible for maxillofacial surgery
the effect of enzyme replacement therapy in mucopolysaccharidosis

Conditions: Mucopolysaccharidosis

Summary: mucopolysaccharidosis (mps) causes chronic, progressive systemic disorders due to enzyme deficiency. musculoskeletal manifestations of mps include bone and vertebral deformities, restricted joint function and rom (range of motion), rib cage abnormalities, short stature and hip dysplasia as well as flexion contracture in the knee and interphalangeal joints and joint laxity. currently, there is no treatment that cures the symptoms of mps. however, there are some forms of treatment that can delay the progression of the disease. enzyme replacement therapy is one such treatment and used for the management of some subtypes of mps disease. enzyme replacement therapy (ert) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (gag) in the tissues. very few studies in the literature have examined the impact of mps in the lives of children affected by this disease. studies investigating functional capacity, independence and quality of life in children receiving or not receiving enzyme replacement therapy have not provided a clear picture of the problems faced by these children. secondly, psychological problems experienced by caregivers of children with mps have not been studied specifically in former studies. therefore, the aim of this study was to examine the impact of ert on aerobic capacity, functional independence and quality of life in children with mps and to determine the anxiety and depression levels of their caregivers.


Eligibility criteria:
inclusion criteria: * age must be range between 3 and 11 years * having diagnosis of mps. exclusion criteria: * patients refusing to participate in the study * patients without a definite diagnosis * patients and parents who are not cooperate with the study tests

Keywords: mucopolysaccharidosis aerobic capacity quality of life functional independence
moral judgements and choices of caregivers in the time of covid-19 pandemic

Conditions: Morals

Summary: the xphi-covid19 randomized study aims to investigate the mechanisms of moral judgements in a population of caregivers, using a survey, with the results to the oxford utilitarianism scale as primary outcome.


Eligibility criteria:
inclusion criteria: * all caregivers from french public healthcare center with intensive care unit * agreement exclusion criteria: * refuse to participate or withdraw agreement

Keywords: morals ethics moral judgements moral choices covid 19 survey utilitarianism deontology oxford utilitarianism scale
12 week study of pf-00734200 for the treatment of type 2 diabetes mellitus in subjects treated with metformin

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of pf-00734200 following oral administration to adult human subjects with t2dm who currently are on a stable dose of metformin.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes * hb1ac \>7%-11% inclusive * male and females 18-70; females must be post-menopausal * on a stable dose of metformin hydrochloride exclusion criteria: * medical history of stroke, unstable angina, heart attack within one year of enrollment, and alcohol dependency or recent drug abuse. * women of childbearing potential, pregnant or nursing * evidence of diabetic complications with significant end-organ damage